Huahai Pharmaceutical's subsidiaries, Huaatai and Huabo Biotech, have been granted the Approval Notice for Drug Clinical Trials for HB0043 Injection by the National Medical Products Administration. HB0043 is an innovative recombinant humanized IgG1 bispecific antibody specifically targeting IL-17A and IL-36R, with the potential to treat a range of autoimmune diseases. The company has dedicated approximately RMB 69.09 million towards research and development costs for this groundbreaking project.

Nevertheless, it is essential to acknowledge that the development journey of pharmaceutical products is typically lengthy and fraught with uncertainties. The competitive landscape within the industry may also evolve significantly over time.